Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rebimastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 17/20 | 1.00 |
| ▸ | MMP9 known ✓ | P14780 | 13/20 | 1.00 |
| ▸ | MMP2 known ✓ | P08253 | 12/20 | 1.00 |
| ▸ | MMP13 known ✓ | P45452 | 7/20 | 1.00 |
| ▸ | MMP14 known ✓ | P50281 | 3/20 | 1.00 |
| ▸ | MMP8 known ✓ | P22894 | 6/20 | 0.59 |
| ▸ | MMP3 | P08254 | 15/20 | 1.00 |
| ▸ | MMP7 | P09237 | 4/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | MMP20 | O60882 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | MMP10 | P09238 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | MMP15 | P51511 | 1/20 | 0.38 |
| ▸ | MMP16 | P51512 | 1/20 | 0.38 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 0.38 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | MMP24 | Q9Y5R2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebimastat SCHEMBL12247619 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP9MMP2MMP13 | |
| Rebimastat SCHEMBL2379355 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP9MMP2MMP13 | |
| Rebimastat SCHEMBL4826862 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP9MMP2MMP13 | |
| Rebimastat SCHEMBL12946005 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP9MMP2MMP13 | |
| Rebimastat SCHEMBL12247626 | 0.94 | MMP1 (0.90) | MMP1MMP3MMP9MMP2MMP13 | |
| Rebimastat SCHEMBL12247617 | 0.94 | MMP1 (0.88) | MMP1MMP3MMP9MMP2MMP13 | |
| SCHEMBL7254495 | 0.91 | MMP9 (0.84) | MMP1MMP3MMP9MMP2MMP13 | |
| SCHEMBL6554608 | 0.91 | MMP9 (0.84) | MMP1MMP3MMP9MMP2MMP13 | |
| SCHEMBL12300383 | 0.91 | MMP1 (0.83) | MMP1MMP3MMP9MMP2MMP13 | |
| SCHEMBL6760102 | 0.89 | MMP3 (0.81) | MMP1MMP3MMP9MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20250221991-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER METASTASES | UNIVERSITY OF CINCINNATI (US) | 2025-07-10 | — | — | US | claimed |
| US-20240226000-A9 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240130962-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES INC (US) | 2024-04-25 | — | — | US | claimed |
| EP-4277616-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | Dyve Biosciences, Inc. (US) | 2023-11-22 | — | — | EP | claimed |
| WO-2023212288-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-02 | — | — | WO | claimed |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | claimed |
| US-20230101403-A1 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | UNIV PENNSYLVANIA (US) | 2023-03-30 | — | — | US | claimed |
| WO-2022155352-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | claimed |
| US-6960567-B2 | Method of producing n-[(2S)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-L-leucyl-L-tert-leucine N-methylamide and intermediate thereof | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | claimed |
| EP-0981366-B1 | SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS | DARWIN DISCOVERY LTD (GB) | 2004-01-21 | — | — | EP | claimed |
| US-20030166506-A1 | Method of producing n-[(2S)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-L-leucyl-L-tert-leucine N-methylamide and intermediate thereof | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | claimed |
| WO-2003048119-A2 | METHOD OF PRODUCING N-[(2S)-SULFANYL-4-(1,5,5-TRIMETHYLHYDANTOINYL)BUTANOYL]-L-LEUCYL-L-TERT-LEUCINE N-METHYLAMIDE AND INTERMEDIATE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | claimed |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2003048119-A2 | METHOD OF PRODUCING N-[(2S)-SULFANYL-4-(1,5,5-TRIMETHYLHYDANTOINYL)BUTANOYL]-L-LEUCYL-L-TERT-LEUCINE N-METHYLAMIDE AND INTERMEDIATE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048119-A2 | METHOD OF PRODUCING N-[(2S)-SULFANYL-4-(1,5,5-TRIMETHYLHYDANTOINYL)BUTANOYL]-L-LEUCYL-L-TERT-LEUCINE N-METHYLAMIDE AND INTERMEDIATE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002087548-A1 | A PHARMACEUTICAL TABLET HAVING A HIGH API CONTENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | SOST, ACP3, KLK3 | MMP1 2213/4885MMP9 276/4885MMP2 1335/4885 |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | PTH1R, SSTR4, MC4R | MMP1 4121/4885MMP9 2649/4885MMP2 3760/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | MMP1 35/4885MMP9 247/4885MMP2 119/4885 |
| US-20030166506-A1 | Method of producing n-[(2S)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-L-leucyl-L-tert-leucine N-methylamide and intermediate thereof | METTL14, BHMT2, BCAT2 | MMP1 4472/4885MMP9 2901/4885MMP2 3367/4885 |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | SSB, METTL16, TLR9 | MMP1 1144/4885MMP9 697/4885MMP2 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.